Suppressive expression of CD274 increases tumorigenesis and cancer stem cell phenotypes in cholangiocarcinoma

Cancer Science

Volumn 105, Issue 6, 2014, Pages 667-674

  Tamai, Keiichi ^a,b   Nakamura, Mao ^a   Mizuma, Masamichi ^b   Mochizuki, Mai ^a,b   Yokoyama, Misa ^a   Endo, Hiroyuki ^a   Yamaguchi, Kazunori ^a   Nakagawa, Takayuki ^a   Shiina, Masaaki ^a   Unno, Michiaki ^b   Muramoto, Koji ^b   Sato, Ikuro ^a   Satoh, Kennichi ^a   Sugamura, Kazuo ^a   Tanaka, Nobuyuki ^a,b  

^a MIYAGI CANCER CENTER RESEARCH INSTITUTE   (Japan)

^b TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Aldehyde dehydrogenase; Cell cycle; Dormancy; Prognosis; Tumorigenicity

Indexed keywords

ALDEHYDE DEHYDROGENASE; PROGRAMMED DEATH 1 LIGAND 1; REACTIVE OXYGEN METABOLITE; SHORT HAIRPIN RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BILE DUCT CARCINOMA; CANCER PROGNOSIS; CANCER STEM CELL; CARCINOGENESIS; CARCINOGENICITY; CELL CYCLE; CELL ISOLATION; CHOLANGIOCARCINOMA CELL LINE; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; MOUSE; NOD SCID GAMMA MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR XENOGRAFT;

ALDEHYDE DEHYDROGENASE; CELL CYCLE; DORMANCY; PROGNOSIS; TUMORIGENICITY;

ALDEHYDE DEHYDROGENASE; ANIMALS; ANTIGENS, CD274; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CARCINOGENESIS; CELL CYCLE; CELL LINE, TUMOR; CHOLANGIOCARCINOMA; HUMANS; IMMUNOMODULATION; MICE; MICE, INBRED NOD; MICE, SCID; NEOPLASTIC STEM CELLS; PHENOTYPE; PROGNOSIS; REACTIVE OXYGEN SPECIES; RNA INTERFERENCE; RNA, SMALL INTERFERING; TRETINOIN; TUMOR MARKERS, BIOLOGICAL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84901803195     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12406     Document Type: Article

References (38)

1. Blechacz B, Komuta M, Roskams T, Gores GJ. Clinical diagnosis and staging of cholangiocarcinoma. Nat Rev Gastroenterol Hepatol 2011; 8: 512-22.
2. Sell S, Dunsford HA. Evidence for the stem cell origin of hepatocellular carcinoma and cholangiocarcinoma. Am J Pathol 1989; 134: 1347-63.
3. Chiba T, Zheng YW, Kita K et al. Enhanced self-renewal capability in hepatic stem/progenitor cells drives cancer initiation. Gastroenterology 2007; 133: 937-50.
4. Magee JA, Piskounova E, Morrison SJ. Cancer stem cells: impact, heterogeneity, and uncertainty. Cancer Cell 2012; 21: 283-96.
5. Lagadinou ED, Sach A, Callahan K et al. BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells. Cell Stem Cell 2013; 12: 329-41.
6. Luo Y, Dallaglio K, Chen Y et al. ALDH1A isozymes are markers of human melanoma stem cells and potential therapeutic targets. Stem Cells 2012; 30: 2100-13.
7. Haraguchi N, Ishii H, Mimori K et al. CD13 is a therapeutic target in human liver cancer stem cells. J Clin Invest 2010; 120: 3326-39.
8. Guan Y, Gerhard B, Hogge DE. Detection, isolation, and stimulation of quiescent primitive leukemic progenitor cells from patients with acute myeloid leukemia (AML). Blood 2003; 101: 3142-9.
9. Holyoake T, Jiang X, Eaves C, Eaves A. Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia. Blood 1999; 94: 2056-64.
10. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003; 100: 3983-8.
11. Yang ZF, Ho DW, Ng MN et al. Significance of CD90+ cancer stem cells in human liver cancer. Cancer Cell 2008; 13: 153-66.
12. Liu G, Yuan X, Zeng Z et al. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer 2006; 5: 67.
13. Maeda S, Shinchi H, Kurahara H et al. CD133 expression is correlated with lymph node metastasis and vascular endothelial growth factor-C expression in pancreatic cancer. Br J Cancer 2008; 98: 1389-97.
14. Zhao P, Li Y, Lu Y. Aberrant expression of CD133 protein correlates with Ki-67 expression and is a prognostic marker in gastric adenocarcinoma. BMC Cancer 2010; 10: 218.
15. Imai T, Tamai K, Oizumi S et al. CD271 defines a stem cell-like population in hypopharyngeal cancer. PLoS ONE 2013; 8: e62002.
16. Topalian SL, Drake CG, Pardoll DM. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol 2012; 24: 207-12.
17. Ghebeh H, Tulbah A, Mohammed S et al. Expression of B7-H1 in breast cancer patients is strongly associated with high proliferative Ki-67-expressing tumor cells. Int J Cancer 2007; 121: 751-8.
18. Yao Y, Tao R, Wang X, Wang Y, Mao Y, Zhou LF. B7-H1 is correlated with malignancy-grade gliomas but is not expressed exclusively on tumor stem-like cells. Neuro Oncol 2009; 11: 757-66.
19. UICC International Union Against Cancer TNM Classification of Malignant Tumours. 7th edn. Hoboken, NJ: Wiley-Blackwell, 2009.
20. Tamai K, Tanaka N, Nara A et al. Role of Hrs in maturation of autophagosomes in mammalian cells. Biochem Biophys Res Commun 2007; 360: 721-7.
21. Tamai K, Tanaka N, Nakano T et al. Exosome secretion of dendritic cells is regulated by Hrs, an ESCRT-0 protein. Biochem Biophys Res Commun 2010; 399: 384-90.
22. Rexer BN, Zheng WL, Ong DE. Retinoic acid biosynthesis by normal human breast epithelium is via aldehyde dehydrogenase 6, absent in MCF-7 cells. Cancer Res 2001; 61: 7065-70.
23. Kimura O, Takahashi T, Ishii N et al. Characterization of the epithelial cell adhesion molecule (EpCAM)+ cell population in hepatocellular carcinoma cell lines. Cancer Sci 2010; 101: 2145-55.
24. Ito M, Hiramatsu H, Kobayashi K et al. NOD/SCID/gamma(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells. Blood 2002; 100: 3175-82.
25. Essers MA, Trumpp A. Targeting leukemic stem cells by breaking their dormancy. Mol Oncol 2010; 4: 443-50.
26. Meng S, Tripathy D, Frenkel EP et al. Circulating tumor cells in patients with breast cancer dormancy. Clin Cancer Res 2004; 10: 8152-62.
27. Tang XH, Gudas LJ. Retinoids, retinoic acid receptors, and cancer. Annual Rev Pathol 2011; 6: 345-64.
28. Meacham CE, Morrison SJ. Tumour heterogeneity and cancer cell plasticity. Nature 2013; 501: 328-37.
29. Jeter CR, Badeaux M, Choy G et al. Functional evidence that the self-renewal gene NANOG regulates human tumor development. Stem Cells 2009; 27: 993-1005.
30. Jeter CR, Liu B, Liu X et al. NANOG promotes cancer stem cell characteristics and prostate cancer resistance to androgen deprivation. Oncogene 2011; 30: 3833-45.
31. Zhang J, Espinoza LA, Kinders RJ et al. NANOG modulates stemness in human colorectal cancer. Oncogene 2013; 32: 4397-405.
32. Bareiss PM, Paczulla A, Wang H et al. SOX2 expression associates with stem cell state in human ovarian carcinoma. Cancer Res 2013; 73: 5544-55.
33. Chen YB, Mu CY, Huang JA. Clinical significance of programmed death-1 ligand-1 expression in patients with non-small cell lung cancer: a 5-year-follow-up study. Tumori 2012; 98: 751-5.
34. Hamanishi J, Mandai M, Iwasaki M et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci USA 2007; 104: 3360-55.
35. Mu CY, Huang JA, Chen Y, Chen C, Zhang XG. High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation. Med Oncol 2011; 28: 682-8.
36. Nomi T, Sho M, Akahori T et al. Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin Cancer Res 2007; 13: 2151-7.
37. Ohigashi Y, Sho M, Yamada Y et al. Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. Clin Cancer Res 2005; 11: 2947-53.
38. Dittfeld C, Dietrich A, Peickert S et al. CD133 expression is not selective for tumor-initiating or radioresistant cell populations in the CRC cell line HCT-116. Radiother Oncol 2010; 94: 375-83.